[XLS] security ownership of cert,https://ir.albireopharma.com/static-files/a585cb67-19a6-4f68-94c9-97b723594295
[XLS] outstanding equity awards - AgroFresh Solutions Inc,https://agrofreshsolutionsinc.gcs-web.com/static-files/1d011edf-755d-4b82-9238-dff2f48c828f
[XLS] https://investor.xenon-pharma.com/static-files/16a...,https://investor.xenon-pharma.com/static-files/16ab3005-9283-4b2d-97e4-60010d3c3bdc
[XLS] https://www.abbottinvestor.com/static-files/9cd49e...,https://www.abbottinvestor.com/static-files/9cd49ea4-6617-4420-81c5-88a9020e2643
[XLS] director compensation-1,https://ir.cogrx.com/static-files/e4fd6e1b-2332-4a8b-a9b3-83c4a69009fa
[XLS] Download XLS - Investor Relations - Frequency Therapeutics,https://investors.frequencytx.com/static-files/4442a995-c8c9-4d20-99d7-524910c6ed74
"[XLS] equity compensation plan i - Investor Relations | Sharecare, Inc.",https://investors.sharecare.com/static-files/937e4112-7dfa-49c4-8e61-f9083fe6c970
[XLS] outstanding equity awards,https://ir.evelobio.com/static-files/63f97a14-7af6-4f8f-be49-9d2462b7f37b
[XLS] equity compensation plan i,https://ir.tusimple.com/static-files/77c89380-2c4a-4592-85ae-60e4ef380f7a
[XLS] audit auditrelated tax and - Precision BioSciences,https://investor.precisionbiosciences.com/static-files/b4bffcf6-9488-4eb5-a23d-415960aff716
[XLS] audit auditrelated tax and - Precision BioSciences,https://investor.precisionbiosciences.com/static-files/25e84859-0a3c-4c4e-a797-6db65ce04239
"[XLS] director compensation - OpGen, Inc.",https://ir.opgen.com/static-files/300b8abf-9013-4fcb-b2f7-e552cf32a01b
[XLS] hookipa pharma inc,https://ir.hookipapharma.com/static-files/341d376c-1a9e-4b20-9d58-b5d410f70a53
[XLS] https://investors.avadel.com/static-files/3226cbbc...,https://investors.avadel.com/static-files/3226cbbc-5be4-4768-b955-8139a6db7e51
[XLS] ie-6 - Investor Relations at World Fuel Services,https://ir.wfscorp.com/static-files/71bcd14d-f213-4b6a-bb69-3666098a1062
"[XLS] Table-6 - TG Therapeutics, Inc.",https://ir.tgtherapeutics.com/static-files/4c237acd-1802-48af-9138-ccdbb574629e
[XLS] director compensation-1,https://investor.logicbio.com/static-files/28493d5f-843a-48c3-91c6-ca1cef14f6c4
[XLS] ocugen inc,https://ir.ocugen.com/static-files/fcfc7a35-8de0-4fcd-af97-4b84c0f659eb
"[XLS] director compensation - El Pollo Loco Holdings, Inc.",https://investor.elpolloloco.com/static-files/fae21b70-f626-4425-b908-6170d3369174
[XLS] 2013 outstanding equity aw-1,https://investors.potbelly.com/static-files/eacd4f46-e5ad-455a-bf25-4f28c38be7c8
[XLS] compensation of directors-1 - Paylocity Investor Relations,https://investors.paylocity.com/static-files/2bc002aa-981a-4ea1-99dc-de234b5c102b
[XLS] how much stock is owned by - Investor Relations | authID.ai,https://investors.authid.ai/static-files/f00d26db-1071-49ad-9065-268b32d6b912
[XLS] summary compensation-1,https://ir.remitly.com/static-files/1f725f62-8c6f-4069-a5eb-c71102de0f44
[XLS] nonemployee director compe,https://ir.accolade.com/static-files/7e8f227d-27b1-420c-bad6-d759e144d9bf
[XLS] director compensation - Lordstown Motors Corp.,https://investor.lordstownmotors.com/static-files/3bcad0d3-04ea-4746-af05-dab84ecc694e
"[XLS] david j hinrichs phd - Investor Relations | Sarepta Therapeutics, Inc.",https://investorrelations.sarepta.com/static-files/954ba2d2-7d15-4588-b118-b9ca6602095e
[XLS] equity compensation plan i - ALB's Investor Relations,http://investors.albemarle.com/static-files/f111a089-1388-4ce1-a0df-d079ca3e4c86
"[XLS] Download XLS - Euronet Worldwide, Inc.",https://ir.euronetworldwide.com/static-files/7736b7d8-724d-4a9c-8580-59c5e8419044
[XLS] option shares granted in t-1,https://investor.lilly.com/static-files/789a1ee4-3af5-4227-89e7-f1cc23f28a6e
[XLS] principal accountant fees - Investor Relations,https://investor.shutterstock.com/static-files/5e2a9ad9-1d4b-4247-b857-0f2da378cb86
[XLS] https://investors.biogen.com/static-files/59e9ce5d...,https://investors.biogen.com/static-files/59e9ce5d-29b2-4be4-a362-6c0d8e350069
[XLS] https://investor.regeneron.com/static-files/0c07b2...,https://investor.regeneron.com/static-files/0c07b22a-7f70-47a6-a791-49211186f935
[XLS] outstanding equity awards -1 - Investor Relations,https://investor.equitybank.com/static-files/e1b559b3-5f07-4535-9571-b6c3a0abb8b2
"[XLS] director compensation - Investors | Fate Therapeutics, Inc.",https://ir.fatetherapeutics.com/static-files/84293f26-a8c9-4541-8c01-c72ef1ddd4f9
[XLS] outstanding equity awards -1 - Altisource Investor Relations,https://ir.altisource.com/static-files/20655da6-730b-49f9-b24f-c34ee95fd483
[XLS] director compensation-1 - Seres Therapeutics,https://ir.serestherapeutics.com/static-files/ebb18948-f606-4210-803b-4306fa0e5e61
[XLS] principal accountant fees,https://investors.poseida.com/static-files/ab61feab-8ed6-4c40-8962-5c39cdf1c68d
[XLS] security ownership of cert - Investor Relations,https://investor.northeastbank.com/static-files/1142cedc-8c08-4dec-b8dd-4b9de26c7e27
[XLS] https://www.dollartreeinfo.com/static-files/f8d707...,https://www.dollartreeinfo.com/static-files/f8d707f4-6880-4a8b-ab1c-1100f541e3df
[XLS] 1 director compensation - Omega Therapeutics,https://ir.omegatherapeutics.com/static-files/4c42662d-035a-4685-846a-f228079b254a
[XLS] https://investors.osi-systems.com/static-files/0cd...,https://investors.osi-systems.com/static-files/0cd4ef9d-dba2-4c29-aebc-89239440b1bc
[XLS] related person transactions - Investors,https://investors.kalarx.com/static-files/078a0d5a-4b5c-44fc-9aee-83e112f0ce84
[XLS] robert w matschullat,https://ir.liveperson.com/static-files/61d4eeb5-f6ec-4701-91ec-557afccf600f
[XLS] director compensation-1 - aTyr Pharma,https://investors.atyrpharma.com/index.php/static-files/3161987a-d711-408f-8cc5-0ba60ef23807
"[XLS] principal accountant fees - Investor Relations | Shift Technologies, Inc.",https://investors.shift.com/static-files/239fc778-c389-4d91-9fae-77e69449d923
[XLS] director compensation,https://ir.arrowheadpharma.com/static-files/862ba68e-5ab0-422d-b1b4-99b0123f3811
[XLS] Download XLS - Duolingo Investor Relations,https://investors.duolingo.com/static-files/b5d04eac-18ac-4b81-9c2c-66106f58630b
[XLS] reappointment of auditors - Gamida Cell,https://investors.gamida-cell.com/static-files/3270091e-1b4f-45c1-bdee-2d6ae0aa3f33
"[XLS] equity compensation plan i - Investor Relations | Xometry, Inc.",https://investors.xometry.com/static-files/a11205ce-de45-42f0-a076-12acd586dc26
[XLS] independent registered pub,https://investors.dyne-tx.com/static-files/c89fa70c-856a-4c25-9490-60da20317e75
[XLS] theratechnologies inc,https://www.theratech.com/static-files/92f0daaa-2faa-4f11-b4c7-67ebcc0849ef
"[XLS] summary compensation - Investor Relations | Xilio Therapeutics, Inc",https://ir.xiliotx.com/static-files/ddb0f921-248b-498e-9edd-7f3b260cd58d
[XLS] director compensation,https://investors.meiragtx.com/static-files/a9b353ea-28bf-4d8d-8d1d-146952c39a94
[XLS] equity compensation,https://ir.orthopediatrics.com/static-files/0b4cfc1c-47b7-4bcf-9d0c-a9a5499abf64
[XLS] director nominees - Investor Overview - vTv Therapeutics Inc.,https://ir.vtvtherapeutics.com/static-files/af35805b-003f-4aa4-b801-1849ae6509cd
[XLS] equity compensation plan i - Spruce Biosciences,https://investors.sprucebiosciences.com/static-files/8d086826-bbf0-4c3e-93b2-a78c45b636d8
[XLS] stock option grants in 2003 - MSA Investor Relations,https://investors.msasafety.com/static-files/348d2e78-c4cb-46ed-b329-1083a4ed1c15
[XLS] summary compensation - Investor Relations | Galecto,https://ir.galecto.com/static-files/a087590c-f698-496b-825a-1024ae40bdfb
[XLS] Download XLS - Investor Relations - DICE Therapeutics,https://investors.dicetherapeutics.com/static-files/84a6142d-4f5f-4f81-b06d-a35eef5c1cbd
"[XLS] nonemployee director compe-2 - Investors | Progyny, Inc.",https://investors.progyny.com/static-files/babf4740-7095-427d-b9ab-0b160d163e1c
[XLS] Table-1 - BioCryst Pharmaceuticals,https://ir.biocryst.com/static-files/3c83ede5-3b17-4d6f-bdd5-de372943b691
[XLS] the board of directors rec,https://ir.imaratx.com/static-files/de7f7953-42b1-4f24-bb5a-68f1758e983e
[XLS] equity compensation plans,https://ir.nationalmi.com/static-files/d24664e2-2545-4458-a30e-2748d1b1aa38
[XLS] equity compensation-4 - Kiniksa Pharmaceuticals,https://investors.kiniksa.com/static-files/78a42418-99f4-4147-b867-92ad8d4b494a
[XLS] ernst young llp - Investor Relations | AppHarvest,https://investors.appharvest.com/static-files/14e4287e-e028-497f-b693-09b135ddf64a
[XLS] director compensation - Investors | Alector,https://investors.alector.com/static-files/cff6b67c-d582-4e7e-8567-aabac55eab07
[XLS] outstanding equity awards -1,https://ir.agtc.com/static-files/e4241b8b-f0de-40c2-95ad-58fb380b755a
[XLS] d outstanding equity award,https://ir.firstmerchants.com/static-files/4e0206eb-8084-4d8b-b026-5222a941588d
[XLS] outstanding equity awards - Cassava Sciences,https://www.cassavasciences.com/static-files/4ca886ac-e1cd-4bef-9b77-683bbb8c0ab6
[XLS] fiscal yearend option values-1 - WillScot Mobile Mini Holdings Corp.,https://www.willscotmobilemini.com/static-files/0a7096c0-03e3-4c8f-994b-45c4dd30391a
